Cx611: Additional Phase IIa data

Pooled data from all 3 dose groups of IV Cx611 (n=46) in a dose-escalation, Spanish Phase IIa trial in 53 patients with RA showed that Cx611 produced an ACR20 response rate of 20%, an ACR50 response r...